Showing results (61-70 of 154) with videos related to

Sort By:
Pageof 16
Scientific Reports|March 11, 2023
Serum levels of IL-4, IL-13 and IL-33 in patients with age-related macular degeneration and myeloproliferative neoplasmsKathrine Gotfredsen, Charlotte Liisborg, Vibe Skov, et al.
Current Drug Targets|December 15, 2010
Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectivesHans Carl Hasselbalch, Thomas Stauffer Larsen, Caroline Hasselbalch Riley, et al.
British Journal of Haematology|July 23, 2025
Prevalence and impact of additional CHIP mutations in JAK2V617F-positive ischaemic cerebrovascular patientsMarie Hvelplund Kristiansen, Vibe Skov, Morten Kranker Larsen, et al.
Ugeskrift for Laeger|June 26, 2020
[Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia]Hans Carl Hasselbalch, Anne Poulsen, Vibe Skov, et al.
Eclinicalmedicine|April 14, 2020
Two-fold risk of pneumonia and respiratory mortality in individuals with myeloproliferative neoplasm: A population-based cohort studyKasper Mønsted Pedersen, Yunus Çolak, Hans Carl Hasselbalch, et al.
Eclinicalmedicine|May 9, 2020
Loss-of-function polymorphism in IL6R reduces risk of JAK2V617F somatic mutation and myeloproliferative neoplasm: A Mendelian randomization studyKasper Mønsted Pedersen, Yunus Çolak, Christina Ellervik, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|March 15, 2019
Smoking and Increased White and Red Blood CellsKasper Mønsted Pedersen, Yunus Çolak, Christina Ellervik, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|September 12, 2015
A new internet-based tool for reporting and analysing patient-reported outcomes and the feasibility of repeated data collection from patients with myeloproliferative neoplasmsNana Brochmann, Ann-Dorthe Zwisler, Mette Kjerholt, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|July 14, 2011
The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosisMalene Risum, Ann Madelung, Henrik Bondo, et al.
Oncoimmunology|September 20, 2018
Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutationMia Aaboe Jørgensen, Morten Orebo Holmström, Evelina Martinenaite, et al.
Pageof 16